Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) EBT Margin (2020 - 2025)

Silence Therapeutics' EBT Margin history spans 6 years, with the latest figure at 229144.12% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 22909422.0% to 229144.12% in Q4 2025 year-over-year; TTM through Dec 2025 was 201.5%, a 30418.0% increase, with the full-year FY2025 number at 192.84%, up 29563.0% from a year prior.
  • EBT Margin hit 229144.12% in Q4 2025 for Silence Therapeutics, up from 13180.5% in the prior quarter.
  • Over the last five years, EBT Margin for SLN hit a ceiling of 229144.12% in Q4 2025 and a floor of 313931.3% in Q1 2021.
  • Historically, EBT Margin has averaged 6984.06% across 5 years, with a median of 348.61% in 2021.
  • Biggest five-year swings in EBT Margin: skyrocketed 31376401bps in 2022 and later crashed -2007838bps in 2025.
  • Tracing SLN's EBT Margin over 5 years: stood at 328.85% in 2021, then increased by 4bps to 315.84% in 2022, then crashed by -126bps to 713.01% in 2023, then soared by 107bps to 49.9% in 2024, then skyrocketed by 459150bps to 229144.12% in 2025.
  • Business Quant data shows EBT Margin for SLN at 229144.12% in Q4 2025, 13180.5% in Q3 2025, and 13672.0% in Q2 2025.